Drug intelligence / Profile preview

cyclophosphamide or azathioprine

Development stage
Phase 1
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

The term **cyclophosphamide or azathioprine** refers to two distinct immunosuppressive agents frequently utilized as alternatives or in sequence for the management of severe autoimmune and inflammatory conditions. **Cyclophosphamide** is a nitrogen mustard alkylating agent that functions by attaching alkyl groups to DNA, leading to intra-strand and inter-strand cross-linking which triggers apoptosis, particularly in rapidly proliferating lymphocytes. **Azathioprine** is a purine antimetabolite and a prodrug of 6-mercaptopurine; it exerts its effect by inhibiting de novo purine synthesis and by being incorporated into DNA and RNA, thereby disrupting nucleic acid synthesis and inhibiting T and B cell proliferation. In clinical practice, cyclophosphamide is often employed for induction therapy in life-threatening diseases like lupus nephritis or systemic vasculitis due to its potent but toxic nature, while azathioprine is commonly used for long-term maintenance therapy to prevent disease relapse.

Brand names
CytoxanNeosarImuranAzasanJayempiImurek
Other names
CyclophosphamideAzathioprineCPAZA6-mercaptopurine prodrug
02

Targets

DNA/RNA (Cellular Deoxyribonucleic Acid and Ribonucleic Acid)PPAT (Amidophosphoribosyltransferase)N7-G (DNA guanine-N7 adduct)

Beyond the preview

Go deeper on cyclophosphamide or azathioprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide or azathioprine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call